Background
Pyroptosis could regulate tumor cell trafficking, invasion, and metastasis, as well as tumor microenvironment (TME). However, prognostic characteristics of pyroptosis-related genes (PRGs) and their impact on the progression of glioma remain insufficient.
Methods
The genetic, transcriptional, and survival data of glioma patients used for bioinformatics analysis were obtained from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases.
Results
We first screened two different molecular subtypes and found that PRG variations were associated with the characteristics of TME cell infiltration, clinicopathological characteristics, and prognosis of patients with glioma. After Cox regression of differentially expressed genes, a risk-score for predicting overall survival (OS) and progression-free survival (PFS) was calculated and its predictive accuracy in glioma patients was then validated. The high-risk group of PRGs signature showed a significantly poor OS compared to the low-risk group (training cohort, p <0.001, validation cohort, p <0.001). A high risk-score implies more immune cell infiltration and a better immunotherapy response to immune checkpoint blockers. Furthermore, the risk-score was significantly associated with the chemotherapeutic drug sensitivity and cancer stem cell (CSC) index. Subsequently, we established a highly accurate nomogram to facilitate the applicability in the preliminary clinical application of the risk-score.
Conclusion
Our findings may lay the foundation for future research targeting pyroptosis in glioma and pave the way for evaluating prognosis and developing more effective immunotherapy strategies.